Immunosuppressant access for the treatment of ICI adverse events
Posted: 31.10.25 by .
Immunosuppressant access for the treatment of ICI adverse events - a IOCN UK-wid
News and Updates
Service Showcase Webinar Launch - Thursday 23rd October
Posted: 21.10.25 by .
Service Showcase Webinar Launch 23/10/2025
Advance the management of immunotherapy toxicities through case conundrums
Posted: 03.10.25 by Alexandra Johnson.
IOCN Event - Advance the management of immunotherapy toxicities through case conundrums
Launching The IOCN Service Showcase Webinar Series!
Posted: 16.09.25 by .
IOCN Service Showcase Webinar Series to showcase nationwide IO Services
Survey: Fertility and the Use of Immune Checkpoint Inhibitor Therapy
Posted: 12.09.25 by .
The purpose of this questionnaire is to detect variation and consistency across UK oncology practice in regards to managing patients of childbearing age who are planned for, or have previously received immune checkpoint inhibitor (ICI) therapy
Deadline Extended for Abstract Submission to IOCN Study Day
Posted: 01.08.25 by .
Deadline Extended for Abstract Submission to IOCN Study Day! Submit until Friday 22nd August!
BOPA Questionnaire - IR-Myocarditis
Posted: 28.07.25 by .
The BOPA Immunotherapy Specialist Interest Group invites IOCN members to complete a survey regarding drug access for IR-myocarditis.
A short survey about Immunotherapy Late Effects services
Posted: 25.07.25 by .
Immunotherapy Late Effects Services Survey
IOCN and UK SACT Board Joint Letter to NHS England
Posted: 24.07.25 by .
IOCN and UK SACT Board Joint Letter to NHS England
BOPA survey on monitoring and treatments for immune related myocarditis
Posted: 17.07.25 by Dr Alexandra Johnson.
Help us understand what cardiac assessments are undertaken prior to ICI therapy and the monitoring during therapy and also discover which drugs, in particular which steroid sparing agents are prescribed for IR-myocarditis.
Showing 0 - 10 of 12 Article/s | Page 1 of 2